Therapeutic use of cannabidiol in Dravet Syndrome: A systematic review
DOI:
https://doi.org/10.33448/rsd-v13i4.45620Keywords:
Cannabidiol; Epilepsies myoclonic; Epilepsy.Abstract
Dravet Syndrome (DS) is an early-onset epileptic encephalopathy that presents with drug-resistant seizures and neurodevelopmental delay. The therapeutic use of cannabidiol (CBD) in the face of DS convulsive patterns brings a new perspective of treatment in cases refractory to conventional therapy, with the aim of improving quality of life. In this systematic review, whose objective is to evaluate and compare the therapeutic response of DS patients to the use of cannabidiol, a careful analysis was carried out of the 9 articles published on the digital platforms PUBMED and SCIELO, between the years 2019 and 2024, about studies that relate DS to the use of CBD. Studies related to epidemiology were excluded and did not meet the inclusion criteria. The use of CBD has been shown to be effective in quantitatively and qualitatively reducing epileptic seizures, improving overall clinical impression, and controlling symptoms associated with DS. In addition, it showed efficacy and tolerability similar to those of the drugs already used, even though more adverse effects were identified than those of the common drugs. The therapeutic use of CBD in children and adults with DS is promising, with a significant reduction in the percentage of seizures and the symptomatology of the syndrome, even if when compared to the usual drugs it presents inferior results. As for the adverse effects related to use, the main difference is the association with other drugs, increasing or decreasing them.
References
Chilcott, E., Díaz, J. A., Bertram, C., Berti, M., & Karda, R. (2022). Genetic therapeutic advancements for Dravet syndrome. Epilepsy & Behavior, 132, 108741.
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., & Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802.
Devinsky, O., Thiele, E. A., Wright, S., Checketts, D., Morrison, G., Dunayevich, E., & Knappertz, V. (2020). Cannabidiol efficacy independent of clobazam: meta‐analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 142(6), 531-540.
Ding, J., Li, X., Tian, H., Wang, L., Guo, B., Wang, Y., ... & Sun, T. (2021). SCN1A mutation—beyond Dravet syndrome: a systematic review and narrative synthesis. Frontiers in Neurology, 12, 743726.
Erku, D., Shrestha, S., & Scuffham, P. (2021). Cost-effectiveness of medicinal cannabis for management of refractory symptoms associated with chronic conditions: A systematic review of economic evaluations. Value in Health, 24(10), 1520-1530.
Gouveia, L. D. G., de Sousa, M. N. A., de Sousa, R. B. D. S., & de Sousa, T. B. D. S. (2021). Uso e eficácia de cannabidiol em pacientes com epilepsia: uma revisão sistemática. Brazilian Journal of Health Review, 4(2), 5209-5220.
Gunning, B., Mazurkiewicz‐Bełdzińska, M., Chin, R. F., Bhathal, H., Nortvedt, C., Dunayevich, E., & Checketts, D. (2021). Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 143(2), 154-163.
Jesus, J. D. T. D. (2021). Síndrome de Dravet: revisão sistemática da terapêutica e perspetivas futuras.
Lattanzi, S., Trinka, E., Striano, P., Rocchi, C., Salvemini, S., Silvestrini, M., & Brigo, F. (2021). Highly purified cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond dravet syndrome and Lennox–Gastaut syndrome. CNS drugs, 35, 265-281.
Lattanzi, S., Trinka, E., Russo, E., Del Giovane, C., Matricardi, S., Meletti, S., & Brigo, F. (2023). Pharmacotherapy for dravet syndrome: a systematic review and network meta-analysis of randomized controlled trials. Drugs, 83(15), 1409-1424.
Lu, H., Ken, M. (2021). Review of the Endocannabinoid System. Biological psychiatry - Cognitive Neuroscience and Neuroimaging, 6(6), 607-615.
Moreira, G. A., Moraes Neto, R., Ribeiro, R. G., & Crippa, A. C. D. S. (2022). Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature. Revista Paulista de Pediatria, 41, e2021197.
Sampaio, R. F., & Mancini, M. C. (2007). Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Brazilian Journal of Physical Therapy, 11, 83-89.
Silvinato, A., Floriano, I., & Bernardo, W. M. (2022). Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associação Médica Brasileira, 68, 1345-1357.
Strzelczyk, A., Lagae, L., Wilmshurst, J. M., Brunklaus, A., Striano, P., Rosenow, F., & Schubert‐Bast, S. (2023). Dravet syndrome: A systematic literature review of the illness burden. Epilepsia Open, 8(4), 1256-1270.
Treves, N., Mor, N., Allegaert, K., Bassalov, H., Berkovitch, M., Stolar, O. E., & Matok, I. (2021). Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Scientific reports, 11(1), 23462.
VanDolah, H., Bauer, B., Mauck, K. (2019). Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clinic proceedings, 94(9), 1840-1851.
Wijnen, B., Witlox, W., Wolff, R., Fayter, D., Ramaekers, B., Otten, T., & Joore, M. (2023). Fenfluramine for treating dravet syndrome: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics, 41(1), 33-42.
Wirrell, E. C., Hood, V., Knupp, K. G., Meskis, M. A., Nabbout, R., Scheffer, I. E., & Sullivan, J. (2022). International consensus on diagnosis and management of Dravet syndrome. Epilepsia, 63(7), 1761-1777.
Wu, J., Zhang, L., Zhou, X., Wang, J., Zheng, X., Hu, H., & Wu, D. (2022). Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis. Frontiers in Pharmacology, 13, 980937.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maria Luiza Luna Sampaio; Vitória de Siqueira Oliveira Nunes; Letícia Elly Santos Fonseca; Lainara Laís Silva dos Santos; Sofia Ramalho Pereira; Marcus Vinicius de Sousa Carvalho Ferreira; Wagner Gonçalves Horta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
